^
    Back
    Association details:
    Biomarker:NPM1-ALK fusion
    Cancer:T Cell Non-Hodgkin Lymphoma
    Drug:Zykadia (ceritinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    ScienceDirect
    Title:

    Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma

    Excerpt:
    A multiple relapsed NPM1-ALK+ ALCL patient treated with ceritinib achieved complete remission...
    DOI:
    10.1016/j.esmoop.2021.100172